In Warren, New Jersey on September 8, 2025, Tevogen Bio Holdings Inc. announced a risk-adjusted net present value (rNPV) estimate ranging from $9 billion to $11 billion for their product TVGN-489. This allogeneic precision T cell therapy is the first clinical-stage product from their ExacTcell™ platform. TVGN-489 is specifically aimed at treating SARS-CoV-2 infection in high-risk vulnerable patients and Long-COVID in patients showing signs of a persistent viral reservoir. Trading under the symbol Nasdaq: TVGN, the Company is focusing on the development and potential impact of this innovative therapy.